Does Radiation Boost Dose Affect Organ Preservation Rates? A Secondary Analysis of the Organ Preservation in Patients With Rectal Adenocarcinoma Trial.
Orly Yariv, Hannah Williams, Karyn A Goodman et al.
✦ AI-curated · Sources linked
In 30 seconds
This secondary analysis of the randomized controlled trial 'Organ Preservation in Patients with Rectal Adenocarcinoma' evaluated the impact of higher radiation boost doses on organ preservation rates in patients with rectal adenocarcinoma. Among 303 eligible patients, the 3- and 5-year probabilities of organ preservation were 52% for the standard-dose group and 47% and 45% for the high-dose group, respectively, indicating no significant association between boost dose and clinical response.
Key findings
- The 3-year probability of organ preservation was 52% for standard-dose patients.
- The 5-year probability of organ preservation was 45% for high-dose patients.
- Clinical complete response rates were similar: 41% for standard-dose and 44% for high-dose.
- Clinical T3/T4 stage was more common in high-dose patients (93%) compared to standard-dose (80%).
Why it matters
Understanding the relationship between radiation boost doses and organ preservation rates is crucial for optimizing treatment strategies in rectal cancer, potentially influencing clinical decision-making regarding neoadjuvant therapy.